Impact of a Tele-rehabilitation Program on People With Multiple Sclerosis

NCT07178834 · tracked via the Priya Life Science Spain tracker

Sponsor

Multiple Sclerosis Center of Catalonia

Phase

Not applicable

Started

2025-02-10

Last updated

2025-09-17

Condition(s) studied

Multiple Sclerosis

Investigational drug(s) / intervention(s)

Telerehab

Telerehab: Adverse events are observed during online rehabilitation with computer vision technology in patients with MS.

Study summary

The goal of this clinical trial is to assessing safety and the occurrence of adverse effects during tele-rehabilitation (TRHB) in people with multiple sclerosis with an EDSS score of 6.5 or lower. The main questions it aims to answer are:

* Intervention using TRHB is considered safe and without adverse effects.
* Intervention using TRHB has a high degree of self-adherence, an impact on physical activity levels and self-efficacy in exercise, and a positive effect on quality of life, mood, and perception of fatigue.

Researchers will compare the tele-rehabilitation with rehabilitation based solely on physical activity recommendations.

Participants will complete three weekly online rehabilitation sessions and must attend three follow-up visits.

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Patients diagnosed with multiple sclerosis confirmed using the 2017 McDonald criteria. * Patients who have the technological means to conduct online sessions and the autonomy to do so. * Patients with cognitive capacity that allows them to sign the informed consent form. * Patients with an internet connection and a device compatible with the Rehub tele-rehabilitation platform (desktop computer, laptop, or tablet). * EDSS level less than or equal to 6.5. Exclusion Criteria: * Participants who are currently undergoing RHB at a center. * Participants who have undergone RHB during the two months prior to the start of the program. * Patients with physical or mental comorbidities that may limit their participation in the rehabilitation program.

Primary outcome measure(s)

Adverse events — From enrollment to the end of treatment in week 8
Adverse events such as falls, pain, fatigue, and others that may occur.

Trial sites (1)

Facility	City	Region	Status
Multiple Sclerosis Center of Catalonia	Barcelona	Spain

Other trials for the same condition

A Study to Evaluate the Efficacy, Safety and Pharmacokinetics (PK) of a Higher Dose of Ocrelizumab in Adults With Relapsing Multiple Sclerosis (RMS) Active, not recruiting

Home-Based Exergame Rehabilitation for Upper Limb Function in People With Multiple Sclerosis Starting soon

Effectiveness of a One-year Group Program for Fatigue Management in Minimally Impaired People With Multiple Sclerosis Active, not recruiting

Advancing Portable Brain Imaging: The NextMRI Project's Role in Revolutionizing Diagnostic MRI Recruiting

Effects of Sensorimotor Insoles on Stability and Gait in Patients With Multiple Sclerosis. Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07178834 on ClinicalTrials.gov ↗ ← All trials in Spain